ArticleEndocrine2026
Prognosis and surgical outcomes of isthmusectomy for cN0 solitary Low-Risk papillary thyroid microcarcinoma in the isthmus.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeThe conventional surgical approach for isthmic papillary thyroid carcinoma (iPTC) has traditionally been total thyroidectomy. This study aimed to evaluate the prognosis and surgical efficacy of isthmusectomy in patients with clinically node-negative (cN0) solitary low-risk isthmic papillary thyroid microcarcinoma (iPTMC).
methodsThis study retrospectively analyzed 201 patients with cN0 solitary low-risk iPTMC who underwent isthmusectomy (IT group) and 374 who underwent total thyroidectomy (TT group) between January 2009 and January 2024. Clinicopathological features and surgical outcomes were compared. Recurrence-free survival (RFS) was assessed using the Kaplan–Meier method. Additionally, trends in surgical approaches for iPTMC were analyzed.
resultsThe IT and TT groups showed significant differences in central lymph node metastasis (CLNM), microscopic, gross extrathyroidal extension (ETE) and median number of metastatic central lymph nodes (CLN) (p < 0.001, p < 0.001, p < 0.001 and p < 0.001, respectively). IT group had significantly lower incidences of postoperative hoarseness, transient and permanent hypocalcemia compared to the TT group (p < 0.001, p < 0.001, and p = 0.011, respectively). The median operative time in IT group was significantly shorter than in TT group (p < 0.001). The TT group was further divided into TTEI+ (with gross ETE) and TTEI− (without gross ETE) groups. Significant differences among the IT, TTEI-, and TTEI + groups were observed in median tumor size, CLNM, microscopic ETE (mETE) and median number of metastatic CLN (p < 0.001, p < 0.001, p < 0.001 and p < 0.001, respectively). Recurrence rates were 4.0%, 4.5%, and 9.3% in IT, TTEI−, and TTEI + groups (p = 0.067). RFS did not differ significantly between IT and TT groups (p = 0.305), but was significantly lower in TTEI + group than in TTEI − group (p = 0.023).
conclusionFor cN0 solitary iPTMC patients, isthmusectomy demonstrated no apparent increase in recurrence risk within the follow-up period of this study and was associated with fewer complications and shorter operative time compared with total thyroidectomy. These findings support isthmusectomy as a potentially reasonable surgical option for carefully selected patients, pending further evaluation of long-term outcomes.
Indexed as
Identifiers
41697553What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.